Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial

Introduction TLR9 agonists are immunomodulators that have been of interest for combined use with cancer immunotherapy. TLR9 agonists, such as lefitolimod (MGN1703), significantly increased Th1 response in preclinical models and have demonstrated efficacy in early clinical trials. This trial assessed...

Full description

Saved in:
Bibliographic Details
Main Authors: Mirella Nardo, Mohamed A. Gouda, Matthew J. Reilley, Amadeo B. Biter, Joann Lim, Stacie A. Bean, Ly M. Nguyen, Priya R. Bhosale, Casey R. Ager, Coline A. Couillault, Sarina A. Piha-Paul, Siqing Fu, Apostolia M. Tsimberidou, Timothy A. Yap, Aung Naing, Jordi Rodon, Vivek Subbiah, Daniel D. Karp, Michael A. Curran, David S. Hong
Format: Article
Language:English
Published: Innovative Healthcare Institute 2025-02-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
immunotherapy
toll-like receptor
checkpoint inhibitor
intratumoral therapy
cancer therapeutics
Online Access:https://jipo.org/doi/pdf/10.36401/JIPO-24-17
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jipo.org/doi/pdf/10.36401/JIPO-24-17

Similar Items